Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Core Insights - Phio Pharmaceuticals' INTASYL compound PH-762 has been awarded the 2025 Immunomodulatory Solution of the Year by the BioTech Breakthrough Awards Program, highlighting its significance in cancer treatment [1][2][3] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Industry Recognition - The BioTech Breakthrough Awards program is an independent initiative that recognizes outstanding achievements in life sciences and biotechnology globally, with a focus on innovative solutions and products [2][9] - The award received by PH-762 underscores its potential as a non-surgical treatment option for patients with cutaneous carcinomas, addressing a significant medical need [3]